Nuveen
COLL icon

Nuveen’s Collegium Pharmaceutical COLL Stock Holding History

Nuveen’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.91M Buy
107,947
+35,957
+50% +$1.23M ﹤0.01% 2230
2026
Q1 		$2.38M Buy
71,990
+2,858
+4% +$121K ﹤0.01% 2206
2025
Q4 		$3.2M Sell
69,132
-3,021
-4% -$126K ﹤0.01% 2099
2025
Q3 		$2.52M Hold
72,153
– – ﹤0.01% 2209
2025
Q2 		$2.13M Sell
72,153
-17,413
-19% -$497K ﹤0.01% 2276
2025
Q1 		$2.67M Hold
89,566
– – ﹤0.01% 2213
2024
Q4 		$2.57M Hold
89,566
– – ﹤0.01% 2279
2024
Q3 		$3.46M Hold
89,566
– – ﹤0.01% 2164
2024
Q2 		$2.88M Buy
89,566
+796
+0.9% +$27.6K ﹤0.01% 2205
2024
Q1 		$3.45M Sell
88,770
-3,559
-4% -$125K ﹤0.01% 2152
2023
Q4 		$2.84M Buy
92,329
+922
+1% +$23.1K ﹤0.01% 2249
2023
Q3 		$2.04M Sell
91,407
-1,300
-1% -$29.6K ﹤0.01% 2286
2023
Q2 		$1.99M Sell
92,707
-77,833
-46% -$1.77M ﹤0.01% 2357
2023
Q1 		$4.09M Sell
170,540
-87,869
-34% -$2.33M ﹤0.01% 1999
2022
Q4 		$6M Buy
258,409
+9,141
+4% +$184K ﹤0.01% 1814
2022
Q3 		$3.99M Sell
249,268
-2,781
-1% -$49K ﹤0.01% 2028
2022
Q2 		$4.47M Buy
252,049
+2,149
+0.9% +$36.2K ﹤0.01% 2019
2022
Q1 		$4.81M Sell
249,900
-770
-0.3% -$14.5K ﹤0.01% 2079
2021
Q4 		$4.68M Sell
250,670
-8,614
-3% -$168K ﹤0.01% 2162
2021
Q3 		$5.12M Sell
259,284
-34,428
-12% -$744K ﹤0.01% 2197
2021
Q2 		$6.94M Buy
293,712
+26,265
+10% +$607K ﹤0.01% 2076
2021
Q1 		$6.34M Sell
267,447
-819
-0.3% -$19.5K ﹤0.01% 2053
2020
Q4 		$5.37M Sell
268,266
-12,171
-4% -$238K ﹤0.01% 2036
2020
Q3 		$5.84M Sell
280,437
-8,120
-3% -$147K ﹤0.01% 1839
2020
Q2 		$5.05M Buy
288,557
+11,509
+4% +$225K ﹤0.01% 1894
2020
Q1 		$4.52M Buy
277,048
+13,748
+5% +$284K ﹤0.01% 1765
2019
Q4 		$5.42M Buy
263,300
+23,475
+10% +$391K ﹤0.01% 1952
2019
Q3 		$2.75M Buy
239,825
+40,466
+20% +$462K ﹤0.01% 2253
2019
Q2 		$2.62M Buy
+199,359
New +$2.67M ﹤0.01% 2299

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Nuveen's COLL Position: Q2 2026 in Review

Nuveen increased its Collegium Pharmaceutical (COLL) stake by 50% in Q2 2026, buying an estimated $1.23M and bringing the position to 107,947 shares worth $3.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

Nuveen first reported a position in COLL in Q2 2019 and has held it in 29 quarters since. The position peaked at $6.94M in Q2 2021. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Nuveen held 107,947 shares of Collegium Pharmaceutical worth $3.91M as of Q2 2026.
  • Nuveen bought 35,957 Collegium Pharmaceutical shares in Q2 2026, an estimated $1.23M.
  • Collegium Pharmaceutical made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2230 holding.
  • Nuveen first reported a position in Collegium Pharmaceutical in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Collegium Pharmaceutical position peaked at $6.94M in Q2 2021.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.